Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus rhamnosus hn001
- Development stage
- Unknown
- Lead developer
- Fonterra
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
**Lacticaseibacillus rhamnosus HN001** is a specific probiotic bacterial strain developed by **Fonterra** and commercialized under the Nutiani HN001 brand. Formerly referred to as **Lactobacillus rhamnosus HN001**, it is a live microbial therapeutic/nutraceutical intended to modulate host immune function, intestinal barrier integrity, and gut microbiome composition rather than acting through a single defined molecular target. Clinical and translational studies have evaluated oral HN001 in prevention of infant eczema and other allergic disease, metabolic indications such as prediabetes and gestational diabetes, and mental well-being or stress-related outcomes, with common study dosing around **6 × 10^9 CFU/day**. Its proposed biology involves microbiome-mediated immune modulation and gut-brain axis effects, but the precise primary target and full mechanism remain incompletely defined.
- Brand names
- Nutiani HN001LactoB HN001
- Other names
- Lactobacillus rhamnosus HN001lacticaseibacillus rhamnosus hn001
Beyond the preview
Go deeper on lacticaseibacillus rhamnosus hn001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus rhamnosus hn001.